Claims for Patent: RE37838

Summary for Patent: RE37838

Title:	Composition for contraception
Abstract:	A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from .[.0.25 to 0.30 mg of.]. drospirenone and .[.0.1 to 0.2 mg of.]. cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
Inventor(s):	Spona; Jurgen (Vienna, AT), Dusterberg; Bernd (Berlin, DE), Ludicke; Frank (Geneva, CH)
Assignee:	Schering Aktiengesellschaft (DE)
Application Number:	09/504,084
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE37838
Patent Claims:	1. A combination product for oral contraception, comprising (a) 23 or 24 dosage units, each containing an estrogen selected from >2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from .[.0.25 to 0.30 mg of.]. drospirenone and .[.0.1 to 0.2 mg of.]. cyproterone acetate, .Iadd.in an amount which is equivalent to 75 .mu.g of gestodene.Iaddend.. and b) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of the 23 or 24 dosage units respectively, is to be followed by 5 or 4, respectively pill-free or placebo pill days. 2. A combination preparation for oral contraception according to claim 1, wherein the estrogen is ethinylestradiol. 3. A combination preparation of claim 2, wherein the gestagen is cyproterone acetate. 4. A combination preparation of claim 2, wherein the gestagen is drospirenone. 5. A combination preparation according to claim 1, wherein the estrogen is present in a dose of 20 .mu.g of ethinylestradiol or an equivalent dose of 17.beta.-estradiol and the gestagen is present in a dose equivalent to 75 .mu.g of .[.gestadene.]. .Iadd.gestodene.Iaddend.. 6. A combination preparation according to claim 1, which comprises 23 dosage units and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle. 7. A combination preparation according to claim 1, which comprises 23 dosage units, each containing 20 .mu.g of ethinylestradiol and a dose of cyproterone acetate or drospirenone equivalent to 75 .mu.g of gestodene and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle. 8. A combination preparation of claim 1, wherein the estrogen is 17.beta.-estradiol. 9. A combination preparation of claim 8, wherein the gestagen is cyproterone acetate. 10. A combination preparation of claim 8, wherein the gestagen is drospirenone..Iadd. 11. A combination preparation of claim 4, which comprises 23 dosage units and 5 placebo pills or other indications to show that no dosage unit or placebo pill is administered during the last 5 days of the menstrual cycle.Iaddend...Iadd. 12. A combination preparation of claim 4, which comprises 24 dosage units and 4 placebo pills or other indications to show that no dosage unit or placebo pill is administered during the last 4 days of the menstrual cycle.Iaddend...Iadd. 13. A combination product for oral contraception, comprising (a) 23 or 24 daily dosage units, each containing 0.020 mg of ethinylestradiol, and an amount of drospirenone which is equivalent to 75 .mu.g of gestodene, and (b) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of the 23 or 24 dosage units, respectively, is to be followed by 5 or 4, respectively, pill-free or placebo pill days, wherein each of the dosage units containing drospirenone contains the same amount of drospirenone.Iaddend.. .Iadd. 14. A combination preparation of claim 13, which comprises 23 dosage units and 5 placebo pills or other indications to show that no dosage unit or placebo pill is administered during the last 5 days of the menstrual cycle.Iaddend...Iadd. 15. A combination preparation of claim 13, which comprises 24 dosage units and 4 placebo pills or other indications to show that no dosage unit or placebo pill is administered during the last 4 days of the menstrual cycle.Iaddend..